

1 **Genetic association studies of fibromuscular dysplasia identify**
2 **new risk loci and shared genetic basis with more common**
3 **vascular diseases**

4

5

6 Adrien Georges^{1#}, Min-Lee Yang^{2,3#}, Takiy-Eddine Berrandou^{1#}, Mark Bakker⁴ Ozan
7 Dikilitas⁵, Soto Romuald Kiando,¹ Lijiang Ma⁶, Benjamin A. Satterfield⁵, Sebanti Sengupta²,
8 Mengyao Yu¹, Jean-François Deleuze⁷, Delia Dupré¹, Kristina L. Hunker^{2,3}, Sergiy
9 Kyrachenko¹, Lu Liu¹, Laurence Amar^{1,8}, Chad M. Brummett⁹, Dawn M. Coleman¹⁰,
10 Valentina d'Escamard¹¹, Peter de Leeuw^{12,13}, Natalia Fendrikova-Mahlay¹⁴, Daniella Kadian-
11 Dodov¹⁵, Jun Z. Li³, Aurélien Lorthioir^{1,8}, Marco Pappaccogli^{16,17}, Aleksander Prejbisz¹⁸,
12 Witold Smigielski¹⁹, James C. Stanley¹⁰, Matthew Zawistowski²⁰, Xiang Zhou²⁰, Sebastian
13 Zoellner²⁰, FEIRI investigators²¹, International stroke genetics consortium (ISGC)
14 intracranial aneurysm working group²¹, MEGASTROKE^{21, 22}, Marc L. De Buyzere²³,
15 Stéphanie Debette²⁴, Piotr Dobrowolski¹⁸, Wojciech Drygas²⁵, Heather L. Gornik¹⁴, Jeffrey
16 W. Olin¹⁵, Jerzy Piwonski²⁵, Ernst R. Rietzschel²⁶, Ynte Ruigrok⁴, Miikka Vikkula²⁷, Ewa
17 Warchol Celinska¹⁸, Andrzej Januszewicz¹⁸, Iftikhar J. Kullo⁵, Michel Azizi^{8,28}, Xavier
18 Jeunemaitre^{1,29}, Alexandre Persu^{16,30}, Jason C. Kovacic^{6,31,32}, Santhi K. Ganesh^{2,3&*}, Nabila
19 Bouatia-Naji^{1&*}

20

21 **Affiliations**

22 ^{1.} Université de Paris, INSERM, Paris Cardiovascular Research Center, F-75006 Paris,
23 France

- 24 ^{2.} Division of Cardiovascular Medicine, Department of Internal Medicine, University of
25 Michigan Medical School, Ann Arbor, MI, USA
- 26 ^{3.} Department of Human Genetics, University of Michigan Medical School, Ann Arbor,
27 MI, USA
- 28 ^{4.} Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain
29 Center, Utrecht University, Utrecht, The Netherlands
- 30 ^{5.} Department of Cardiovascular Medicine, Mayo Clinic, Rochester MN 55902 USA
- 31 ^{6.} Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at
32 Mount Sinai, New York, NY, USA
- 33 ^{7.} Centre National de Recherche en Génomique Humaine, Institut de Génomique, CEA
34 and Fondation Jean Dausset-CEPH, Evry, France
- 35 ^{8.} Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges
36 Pompidou, F-75015 Paris, France
- 37 ^{9.} Department of Anesthesiology, Michigan Medicine, University of Michigan, Ann
38 Arbor, MI, USA
- 39 ^{10.} Vascular Surgery Section, Department of Surgery, Michigan Medicine, University of
40 Michigan, Ann Arbor, MI, 48109, USA
- 41 ^{11.} Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
42 USA
- 43 ^{12.} Department of Internal Medicine, Division of General Internal Medicine, Section
44 Vascular Medicine, Maastricht University Medical Centre, Maastricht University,
45 Maastricht, the Netherlands
- 46 ^{13.} CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre,
47 Maastricht University, Maastricht, the Netherlands
- 48 ^{14.} Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA

- 49 15. Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R.
50 Kravis Center for Cardiovascular Health Icahn School of Medicine at Mount Sinai.
- 51 16. Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de
52 Louvain, 1200 Brussels, Belgium
- 53 17. Division of Internal Medicine and Hypertension Unit, Department of Medical
54 Sciences, University of Turin, Turin, Italy
- 55 18. Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
- 56 19. Department of Demography, University of Lodz, Lodz, Poland
- 57 20. Department of Biostatistics and Center for Statistical Genetics, University of
58 Michigan School of Public Health, Ann Arbor, MI, USA
- 59 21. A full list of authors and their affiliations is provided in the supplementary material.
- 60 22. Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Labex
61 DISTALZ - Risk factors and molecular determinants of aging-related disease, F-
62 59000 Lille, France
- 63 23. Department of Cardiovascular Diseases, Ghent University and Ghent University
64 Hospital, Ghent, Belgium
- 65 24. Department of Neurology, Bordeaux University Hospital, Inserm U1219, Bordeaux,
66 France
- 67 25. Department of Epidemiology, Cardiovascular Disease Prevention, and Health
68 Promotion, National Institute of Cardiology, Warsaw, Poland
- 69 26. Department of Cardiovascular Diseases, Ghent University and Ghent University
70 Hospital, Ghent, Belgium
- 71 27. Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain,
72 1200 Brussels, Belgium

73 ^{28.} Université de Paris, Inserm, Centre d'Investigation Clinique 1418, F-75006, Paris,
74 France

75 ^{29.} Department of Genetics, Assistance-Publiques-Hôpitaux de Paris, Hôpital Européen
76 Georges Pompidou, F-75015 Paris France

77 ^{30.} Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique,
78 Université Catholique de Louvain, 1200 Brussels, Belgium

79 ^{31.} Victor Chang Cardiac Research Institute, Darlinghurst, Australia

80 ^{32.} University of New South Wales, Sydney, Australia

81 # First authors

82 & Last authors

83 * Corresponding authors.

84

85

86 **ABSTRACT**

87 Fibromuscular dysplasia (FMD) is an arteriopathy that presents clinically by hypertension and
88 stroke, mostly in early middle-aged women. We report results from the first genome-wide
89 association meta-analysis of FMD including 1962 FMD cases and 7100 controls. We
90 confirmed *PHACTR1* and identified three new loci (*LRP1*, *ATP2B1*, and *LIMA1*) associated
91 with FMD. Transcriptome-wide association analysis in arteries identified one additional locus
92 (*SLC24A3*). FMD associated variants were located in arterial-specific enhancers active in
93 vascular smooth muscle cells and fibroblasts. Target genes are broadly involved in
94 mechanisms related to actin cytoskeleton and intracellular calcium homeostasis, central to
95 vascular contraction. Cross-trait linkage disequilibrium analyses identified positive genetic
96 correlations with blood pressure, migraine and intracranial aneurysm, and an inverse
97 correlation with coronary artery disease, independent from the genetics of blood pressure.

98

99 **Introduction**

100 Cardiovascular disease (CVD) is the primary cause of mortality in the world. CVD causes
101 ~18 million deaths each year, of which 85% are due to stroke and myocardial infarction
102 (MI)¹. Renal artery stenosis is a cause of hypertension, a preventable risk factor for stroke and
103 MI. Renovascular hypertension results from numerous factors, which include atherosclerosis
104 or fibromuscular dysplasia (FMD) in ~10% of cases². While atherosclerosis has been widely
105 studied and its genetic architecture has been well defined, little is known about the
106 pathogenesis or genetics of FMD. To date, only *PHACTR1*, a pleiotropic locus involved in
107 the genetic risk of several cardiovascular and neurovascular diseases, has been reported to be
108 associated with FMD³.

109 FMD occurs predominantly in early middle-aged women (mean age at diagnosis 46-53
110 years)⁴, thus representing a subset of the population where cardiovascular and neurovascular
111 disease present differently depending on sex^{5,6}. FMD is an idiopathic, segmental, non-
112 atherosclerotic disease of the arterial walls, leading to stenosis of small and medium-sized
113 arteries, often associated to dissection, aneurysm, and in some cases arterial tortuosity^{4,7-9}.
114 The prevalence of FMD is hard to estimate due to the need of comprehensive vascular
115 imaging to make a definitive diagnosis while concurrently excluding the presence of
116 atherosclerotic plaques. Diagnosis is often made incidentally on imaging (~3-4% in healthy
117 kidney donors¹⁰), as part of an investigation to elucidate early onset and/or resistant
118 hypertension, following a stroke event or spontaneous coronary artery dissection, a form of
119 acute myocardial infarction associated with female sex as well¹¹.

120 Investigating the genetic basis of FMD has been a challenging endeavour due to two main
121 reasons: *i*) poor recognition from the general medical community of this underestimated cause
122 of arterial stenosis due to its atypical presentation in women with few cardiovascular risk
123 factors, who are theoretically considered as protected from CVD; *ii*) the effort needed to

124 collect large cohorts of patients where adequate imaging through computed tomographic
125 angiography or magnetic resonance angiography was conducted to precisely define the non-
126 atherosclerotic phenotype and provide sufficient power to conduct genetic studies⁴.

127 Here we report findings from a meta-analysis of six genome-wide association studies
128 (GWAS) from Europe and the United States of America to investigate the genetic basis of
129 FMD in 1962 patients and 7100 controls. We conducted a single nucleotide polymorphism
130 (SNP)-level GWAS, gene-based GWAS, and transcriptome-wide association study (TWAS)
131 in arteries. We confirmed the previously associated locus *PHACTR1* and identified three
132 novel risk loci associated with FMD at the SNP level and several novel genes associated to
133 FMD at the gene or transcriptome level. Through the integration of annotation datasets
134 generated in fibroblasts, smooth muscle and endothelial cells, combined with public resources
135 available in arteries, we prioritized variants and identified target genes in most loci. We found
136 that risk genes for FMD are specifically and consistently expressed in smooth muscle cells,
137 fibroblasts and arterial tissue and are involved in regulatory mechanisms related to actin
138 cytoskeleton and intracellular calcium homeostasis, a mechanism central to vascular
139 contraction. Using linkage disequilibrium score regression, we found an important genetic
140 overlap between FMD and blood pressure, migraine, intracranial aneurysm, coronary artery
141 disease and MI, and demonstrated that genetics of blood pressure is not driving the genetic
142 association or correlation with FMD.

143

144 **RESULTS**

145

146 **Meta-analysis of six genome-wide association studies revealed new risk loci for FMD**

147 We tested ~6.5 million common genetic variants (MAF>0.01) in 1962 FMD cases and 7100
148 controls. All studies involved participants of European ancestry and were adjusted for sex, the
149 first five principal components and individual study genomic control. Three loci contained
150 SNPs associated with FMD at the genome-wide significance level (**Supplementary Figure**
151 **S1, Table 1, Figure 1a**); the previously identified *PHACTR1* locus on chromosome 6 (lead
152 SNP rs9349379, OR=1.39, 95%CI: 1.28-1.51, $P = 2.0 \times 10^{-14}$), *LRPI* on chromosome 12
153 (rs11172113, OR=1.31, 95%CI: 1.20-1.43, $P = 2.6 \times 10^{-10}$) and rs17249754, located 10kb
154 downstream of *ATP2B1* on chromosome 12 as well (OR=1.41, 95%CI: 1.26-1.58, $P =$
155 5.9×10^{-9}). A GWAS restricted to multifocal FMD, which is characterized by multiple stenoses
156 and is the major FMD subtype (91%, **Supplementary Table S1**), identified one additional
157 signal in *LIMAI* on chromosome 12 (rs6580732, OR=1.30, 95%CI: 1.19- .41, $P = 2.2 \times 10^{-9}$,
158 **Figure 1a, Supplementary Figure S1, Table 1**). Despite mapping to the same chromosome,
159 *LIMAI*, *LRPI* and *ATP2B1* loci are fully independent and map on positions 50.5, 57.5 and
160 90.1 megabases on chromosome 12, respectively. A GWAS in women only cases (87% of
161 patients) identified the same four loci as significantly associated with FMD, with comparable
162 effect sizes and levels of significance (**Supplementary Figure S1, Table 1, Supplementary**
163 **Tables S2-S4**). Given the small sample size (N=247), a GWAS in men only was not
164 conducted.

165

166 **FMD associated variants regulate the expression of nearby genes in arterial tissues**

167 To identify potential target genes at FMD associated loci, we queried the GTEx database for
168 eQTL association of lead variants in all tissues available (v8 release, **Figure 2a**)¹².

169 Interestingly, the lead SNPs in all four loci were identified among top eQTLs of at least one
170 nearby gene in one or more of the three available arterial tissues (**Figure 2a**).

171 At the *PHACTR1* locus, FMD risk allele (rs9349379-A) was associated with increased
172 *PHACTR1* expression in all arterial tissues analysed ($P_{Artery-Tibial}=8.0\times 10^{-42}$, **Figure 2b**, $P_{Artery-}$
173 $Aorta=2.0\times 10^{-17}$, $P_{Artery-Coronary}=3.0\times 10^{-9}$). Colocalization analyses between eQTLs in arterial
174 tissues and FMD association strongly supported rs9349379 to be the causative variant on this
175 locus (posterior probability 99.2%, **Figure 2c**). *PHACTR1* encodes a member of the
176 phosphatase and actin regulator family of proteins implicated in the reorganisation of actin
177 cytoskeleton and tubule formation. Interestingly, rs9349379-*PHACTR1* expression correlation
178 was also found in primary dermal fibroblasts cell lines from FMD patients (N=83) and
179 matched controls (N=70). This finding was observed when all samples were jointly analysed
180 ($P = 0.01$), in the FMD group only ($P = 0.01$), but not in the control group (**Supplementary**
181 **Figure S2**).

182 At the *LRPI* locus, rs11172113 was highly correlated with *LRPI* expression in tibial arteries
183 ($P_{Artery-Tibial}=9.4\times 10^{-21}$, **Figure 2d**), aorta ($P_{Artery-Aorta}=3.6\times 10^{-15}$) and to a lesser extent
184 coronary artery tissues ($P_{Artery-Coronary}=2.4\times 10^{-4}$). The FMD risk allele (rs11172113-T) was
185 associated with increased expression of *LRPI* and rs11172113 was also supported by the
186 colocalization analysis as the most likely causal variant at this locus (Posterior probability
187 99.2%, **Figure 2e**) *LRPI* encodes low density lipoprotein receptor related protein 1, a
188 scavenger receptor involved in numerous cellular processes including intracellular signalling.

189 As for the *ATP2B1* locus, the strongest eQTL association involving rs17249754 in artery
190 tissue was with *ATP2B1* in tibial arteries ($P_{Artery-Tibial}=1.5\times 10^{-17}$, **Figure 2f**) and aorta samples
191 ($P_{Artery-Aorta}=5.1\times 10^{-5}$), whereas no association was detected in coronary arteries. The FMD
192 risk allele (rs17249754-G) was associated with decreased expression of *ATP2B1* in arterial
193 tissues (**Figure 2f**). Colocalization analysis of FMD association and expression in arterial

194 tissue supports a common causal variant (posterior probability 85.5%, **Figure 2g**). We note
195 that the *ATP2B1* antisense transcript (*ATP2B1-AS*) was also predicted as potentially regulated
196 by the same causal variant (posterior probability 76.6%, **Supplementary Figure S3a**).
197 *ATP2B1* encodes the ATPase plasma membrane Ca²⁺ transporting 1 involved in intracellular
198 calcium homeostasis.

199 Several eQTL signals were found at the *LIMAI* locus, but none colocalized clearly with the
200 FMD association signal (**Figure 2i, Supplementary Figure S3b-d**). *ATF1* was the strongest
201 eQTL protein-coding gene in arterial tissues ($P_{Artery-Aorta}=1.4\times 10^{-14}$, **Figure 2h**, $P_{Artery-}$
202 $Tibial}=8.9\times 10^{-13}$, $P_{Artery-Coronary}=1.7\times 10^{-3}$), with FMD risk allele (rs6580732-T) being associated
203 with lower expression of *ATF1* (**Figure 2h**). However, colocalization analysis of these two
204 signals was inconclusive (posterior probability = 0.6%, **Figure 2i**). *LIMAI* encodes LIM
205 domain and actin binding 1 involved in actin filament depolymerisation while *ATF1* is the
206 gene encoding activating transcription factor 1, an activating transcription factor involved in
207 cell growth and survival.

208

209 **Gene-based association and transcriptome-wide association studies identify additional** 210 **FMD associated genes**

211 GWAS efficiently captures the effect of single variants affecting traits or diseases but may not
212 detect the combined effect of multiple variants independently affecting disease outcome and
213 located in the same gene. To address this limitation in our genetic investigation, we
214 performed gene-based association analyses using MAGMA¹³, a regression-based gene and
215 gene-set analyses for GWAS data implemented in FUMA¹⁴. We identified four genes, all on
216 chromosome 12 from two different loci to be associated with FMD in at least one of the tested
217 conditions (all FMD cases, multifocal FMD, women only, Bonferroni corrected $P<0.05$,
218 **Figure 1b, Table 2**). These included three genes at the *LIMAI* locus (*LIMAI*, $P_{Women}=3.0\times 10^{-}$

219 ⁷, *ATF1*, $P_{Multifocal}=7.3\times 10^{-7}$ and *GPD1*, $P_{Multifocal}=7.3\times 10^{-7}$) and *STAT6*, located near *LRP1*
220 ($P_{Multifocal}=2.4\times 10^{-6}$).

221 To get a global view of the potential transcriptional effects of FMD associated variants in
222 arteries, we conducted a TWAS using the FUSION software¹⁵, and gene expression models
223 calculated from tibial artery eQTL analysis from GTEx (v7 release). In line with FMD
224 association and eQTLs analyses, we found a significant association between genetically
225 predicted expression levels of *PHACTR1* ($P = 1.1\times 10^{-11}$), *LRP1* ($P = 2.7\times 10^{-10}$) and *ATP2B1*
226 ($P = 3.7\times 10^{-6}$) in arterial tissue and FMD (**Table 2, Figure 1c-d, Supplementary Table S4**).

227 No gene in the *LIMAI* locus was identified as a TWAS hit, although genetically predicted
228 expression of *ATF1* and *LIMAI* were suggestively associated with FMD ($P_{ATF1} = 2\times 10^{-3}$,
229 $P_{LIMAI} = 7\times 10^{-3}$, **Table 2**).

230 In addition to genes located in close proximity of genome-wide FMD-associated loci, we
231 found *SLC24A3* (chromosome 20) to be a robust TWAS hit in tibial artery samples ($P =$
232 5.1×10^{-9} , **Figure 1c-d**). Of note, *SLC24A3* was also a suggestive hit in the gene-based
233 association study ($P_{All}=4.5\times 10^{-6}$) (**Table 2**). *SLC24A3* overlaps two independent and
234 suggestive FMD association signals (lead SNP: rs2424245, $P = 4.0\times 10^{-7}$, secondary SNP:
235 rs6046121, $P = 1.2\times 10^{-5}$, correlation $r^2<0.01$, **Supplementary Figure S4**). FMD risk alleles
236 of both variants associated with lower *SLC24A3* expression in artery tissue (rs6046121-A:
237 $P_{Tibial\ artery} = 2.0\times 10^{-11}$, $P_{Aorta} = 5.6\times 10^{-6}$; rs2424245-T: $P_{Tibial\ artery} = 1.6\times 10^{-4}$, **Supplementary**
238 **Figure S4**). Similar to *ATP2B1*, *SLC24A3* encodes a plasma membrane calcium exchanger
239 also involved in intracellular calcium homeostasis. Results obtained from TWAS using
240 multifocal FMD and women FMD are reported in **Supplementary Figure S5** with overall
241 comparable findings to the whole sample findings.

242

243

244 **FMD associated genes are expressed in vascular smooth muscle cells and fibroblasts**

245 We looked-up the expression of FMD associated genes (**Table 2**) in publicly available mouse
246 aorta single cell RNA-Seq data¹⁶, 665 tibial artery RNA-Seq samples from GTEx and 153
247 primary dermal fibroblasts cell lines derived from FMD patients (N = 83) and matched
248 controls (N = 70). Mouse aorta single cell experiment shows that *Phactr1*, *Lrp1*, *Atp2b1*, *Atf1*,
249 *Lima1*, *Slc24a3* and *Stat6* were mostly detected in vascular smooth muscle cells (VSMC) and
250 *Phactr1*, *Lrp1*, *Atp2b1*, *Atf1*, *Lima1* and *Stat6* in fibroblasts clusters, whereas only *Atp2b1* and
251 *Lima1* showed strong presence in endothelial cells (EC) clusters (**Supplementary Figure**
252 **S6**).

253 On the other hand, expressions of all the FMD-associated genes were detected in human tibial
254 artery samples from GTEx, although *GPD1* had very low and variable expression levels
255 compared to the other genes (**Supplementary Figure S7**). Interestingly, *SLC24A3* was less
256 expressed in arterial samples of women ($P = 1.1 \times 10^{-5}$, **Supplementary Figure S8**), consistent
257 with its predicted decreased expression in FMD risk allele carriers. A trend toward higher
258 expression in women was observed for *PHACTR1* and *ATF1* ($P = 0.013$, **Supplementary**
259 **Figure S8**), also these were consistent with the direction of effect of the FMD increasing risk
260 alleles for *PHACTR1* but not for *ATF1*. However, we did not observe any differences in the
261 expression of top FMD associated genes between fibroblasts samples derived from an all
262 women group of FMD patients and those from sex-matched controls (**Supplementary Figure**
263 **S9**).

264

265 **FMD associated variants are located in regulatory elements active in arterial tissue and**
266 **VSMCs**

267 The FMD associated variants identified in this study are all located in non-coding regions,
268 either intronic or intergenic. To obtain insights into their potential regulatory function, we

269 generated open chromatin profiles in human carotid artery-derived primary cells (two VSMC
270 and two EC primary cell lines), human coronary artery derived cells (one VSMC and one EC
271 primary cell line), human dermal (two cell lines) and cardiac fibroblasts (one cell line) using
272 ATAC-Seq. We also reanalysed existing data obtained using ATAC-Seq on healthy coronary
273 arteries¹⁷. Using a common pipeline analysis, we obtained 177,015 to 196,272 peaks from
274 cultured human VSMCs, 120,577 to 137,779 from ECs and fibroblasts, and 54,622 to 70,855
275 peaks from human coronary arteries (**Figure 3a**). Global correlation and principal component
276 analyses showed that open chromatin regions of fibroblasts and VSMCs are closely related,
277 whereas ECs and artery samples form separate clusters (**Figure 3b-c**).

278 Using the GREGOR algorithm¹⁸, we found that FMD-associated variants were enriched
279 among open chromatin peaks in artery tissue samples (average 1.6-fold enrichment, *P*-values:
280 9×10^{-5} - 1×10^{-2}), but not in VSMCs, ECs, or fibroblasts (**Figure 3d**). We found that, globally,
281 artery-specific ATAC-Seq peaks are overrepresented in the vicinity of genes involved in
282 contractile fibres and muscle system processes (**Figure 3e-f**).

283 Next, we annotated FMD associated variants with overlapping open chromatin regions we
284 generated in cells and re-analysed in coronary arteries, in addition to histone marks in artery
285 tissue previously generated through the ENCODE project. We defined as potentially causal
286 all variants that overlapped open chromatin peaks in at least one of the above-mentioned
287 arterial tissues or cell types (**Table 3**). Our analyses identified to at least one causal variant
288 per locus. At the *PHACTR1* locus on chromosome 6, the lead variant (rs9349379) belonged to
289 a chromatin region open in arterial tissue but not accessible in VSMCs, fibroblasts or ECs.
290 This variant also overlapped with well-defined enhancer marks in arterial tissue and is
291 strongly supported as the causal variant in this locus (**Figure 4a-b**).

292 The lead variant rs11172113 in *LRPI* overlapped with open chromatin peaks in arterial tissue,
293 primary VSMCs and fibroblasts, but not primary ECs (**Figure 4c-d**). Strong enhancer and

294 promoter marks were also present in arterial tissue in this region, which mapped 5kb
295 downstream of *LRPI* promoter.

296 The *ATP2B1* locus included three highly associated variants (rs11105352, rs11105353 and
297 rs11105354, **Figure 4e**), which all overlapped a small open-chromatin peak specifically
298 observed in arterial tissue, and an enhancer-specific H3K4me1 histone mark (**Figure 4f**). Of
299 note, a suggestively associated SNP (rs73437382, $P = 2.9 \times 10^{-6}$), in moderate LD ($r^2 = 0.5$)
300 with rs11105354 was located in the promoter sequence of *ATP2B1* and *ATP2B1-AS1* and is
301 thus candidate for causality (**Figure 4e**).

302 Finally, in the FMD multifocal specific locus *LIMA1*, there were ~100 tightly correlated
303 variants spanning over 500kb (**Figure 4g**), but only three genome-wide significant variants
304 intronic to *LIMA1* overlapped open chromatin regions (**Figure 4h, Table 3**). rs7301566
305 overlaps a region active in arteries, VSMCs and fibroblasts and strong enhancer marks in
306 arteries (**Figure 4h**). rs1109726, a suggestively associated variant, shows several marks of
307 regulatory function and maps to the promoter of *ATF1*, ~480kb downstream of *LIMA1*
308 (**Figure 4h**).

309

310 **FMD loci are associated with blood pressure traits but hypertension did not drive** 311 **genetic association with FMD**

312 FMD diagnosis is often made through radiographic imaging to investigate vascular anomalies
313 in the context of pre-existing and unexplained hypertension, following a stroke event such as
314 due to cervical artery dissection or following MI due to spontaneous coronary artery
315 dissection. To investigate the potentially shared genetic basis of these clinical associations,
316 we curated previously published GWAS on diseases of interest, mainly from GWAS catalog
317 and the UK Biobank summary statistics database (<http://www.nealelab.is/uk-biobank>). We

318 restricted our curation to FMD lead variants and their proxies ($r^2 \geq 0.5$, Europeans from 1000
319 Genomes phase 3).

320 Strikingly, all FMD loci were previously associated with at least one trait related to blood
321 pressure, with the same alleles being associated with increased FMD risk and higher blood
322 pressure/hypertension risk (**Figure 5a**). FMD loci were all associated ($P \leq 5 \times 10^{-8}$) with pulse
323 pressure and at least suggestively ($P \leq 1 \times 10^{-5}$) associated with hypertension, systolic blood
324 pressure and diastolic blood pressure. The lead variants in *SLC24A3* that we identified in the
325 gene-based association and TWAS were associated with blood pressure traits as well (**Figure**
326 **5a**).

327 Hypertension is reported in a large proportion of patients with FMD in general, and in the
328 majority of FMD cases in this study (51 to 80% of FMD cases, **Supplementary Table S1**).

329 To test for hypertension as a potential confounder driving the observed association signals,
330 we conducted both stratified and adjusted analyses for hypertension status for the GWAS lead
331 variants in the two largest cohorts of our meta-analysis: the French and the UM case control
332 studies (**Supplementary Table S6**). Adjustment for hypertension status marginally modified
333 the effects sizes and level of significance of the associations with FMD at all four loci,
334 including when the association was absent (*LIMAI* in the French study). Given the large
335 proportion of hypertension both in the cases and the controls of the French study, associations
336 with FMD were only observed in the larger stratum of hypertensive patients. However, all
337 four loci showed significant association with FMD both in hypertensive and non-hypertensive
338 individuals in the UM case control study, supporting that these loci impact FMD risk
339 independent of hypertension status in the FMD cases. Concordantly, in the meta-analysis
340 including all 6 individual studies, FMD associations at the top loci remained significant after
341 conditioning FMD association on the genetic association with systolic blood pressure

342 obtained from the recent, large-scale blood pressure GWAS meta-analysis¹⁹ (**Supplementary**
343 **Table S7**).

344

345 **FMD associated loci have pleiotropic associations with multiple vascular diseases**

346 In addition to blood pressure, we investigated additional associations of the FMD-associated
347 loci and genes with several vascular diseases (**Figure 5a**). *PHACTR1*, *LRP1* and *SLC24A3*
348 have been previously associated with migraine, with the same alleles at risk for FMD and
349 migraine. *PHACTR1* and *LRP1* were both involved in a wide range of vascular diseases,
350 including cervical artery dissection and spontaneous coronary artery dissection, in addition to
351 abdominal aortic aneurysm for *LRP1*. *PHACTR1* and *ATP2B1* were associated with coronary
352 artery disease (CAD) and MI, while *LRP1* was suggestively associated to CAD, and in all
353 three loci the risk alleles were the opposite of those associated with FMD. Colocalization of
354 FMD association signals with the most relevant traits, in addition to the comparison of FMD
355 TWAS in tibial arteries with the other diseases (**Figure 5b**), suggested that the same variants
356 cause the associations with FMD, cervical artery dissection, migraine and CAD
357 (**Supplementary Figure S10**).

358

359 **Genetic relationships between FMD, cardiovascular and neurovascular diseases**

360 In light of the important number of diseases where FMD loci and genes are involved, we used
361 LD score regression²⁰ to calculate the genome-wide correlation between FMD and blood
362 pressure traits, CAD and MI, migraine, several stroke sub-types, lipids and clinical traits
363 related to renal function (**Figure 6a-b, Supplementary Table S8**). FMD was positively
364 correlated with hypertension ($r_g = 0.37$, $P = 4 \times 10^{-8}$), systolic blood pressure ($r_g = 0.44$, $P =$
365 5×10^{-10}), diastolic blood pressure ($r_g = 0.39$, $P = 2 \times 10^{-9}$) and pulse pressure ($r_g = 0.36$, $P =$
366 1×10^{-8}). FMD also correlated positively with migraine ($r_g = 0.37$, $P = 2 \times 10^{-4}$), intracranial

367 aneurysm (pooled ruptured and unruptured, $r_g = 0.34$, $P = 7 \times 10^{-6}$), aneurysmal subarachnoid
368 haemorrhage ($r_g = 0.37$, $P = 4 \times 10^{-5}$), and cervical artery dissection, although this latter did not
369 survive correction for multiple testing ($r_g = 0.78$, $P = 1 \times 10^{-2}$). FMD was not genetically
370 correlated with several stroke subtypes, CAD and MI. We also found a negative genetic
371 correlation between FMD and low-density lipoprotein cholesterol levels ($r_g = -0.19$, $P = 1 \times 10^{-3}$).
372 No significant correlation with any of the kidney function related traits was observed
373 (**Figure 6b, Supplementary Table S8**). Interestingly, genetic correlations after conditioning
374 the FMD associations results on genome-wide genetic associations with systolic blood
375 pressure revealed a significant negative genetic correlation with CAD ($r_g = -0.29$, $P = 6 \times 10^{-5}$)
376 and MI ($r_g = -0.28$, $P = 2 \times 10^{-3}$) (**Figure 6c, Supplementary Table S9**), indicating that this
377 opposite genetic relation between FMD and CAD/MI is not mediated by common loci
378 between FMD and systolic blood pressure. FMD genetic correlation with migraine was only
379 marginally affected by conditioning on systolic blood pressure genetics ($r_g = 0.38$, $P = 8 \times 10^{-5}$).
380 On the other hand, the genetic correlations with intracranial aneurysm, subarachnoid
381 haemorrhage and low-density lipoprotein cholesterol levels were less significant after
382 conditioning on systolic blood pressure genetics, indicating that these correlations with FMD
383 are in part due to the common genetic associated loci between FMD and systolic blood
384 pressure (**Figure 6c-d, Supplementary Table S9**). The correlation results were comparable
385 when we conducted the analyses after removing the top FMD associated loci
386 (**Supplementary Tables S10 and S11**).

387

388 **DISCUSSION**

389 Our study is the most comprehensive genetic investigation dedicated to FMD, a non-
390 atherosclerotic arterial disease primarily afflicting middle-aged women with few classical
391 cardiovascular risk factors. Key findings from our study include: *i*) Single SNP GWAS, gene-
392 based GWAS and TWAS analyses in arteries identified three novel risk loci for FMD and
393 involved novel genes while confirming *PHACTR1*, the only known risk locus for FMD. *ii*)
394 Through integration of annotation datasets generated inhouse, combined with public
395 resources, we provided detailed prioritization of FMD risk variants and genes. We found that
396 FMD risk genes are consistently and specifically expressed in VSMCs, fibroblasts and arterial
397 tissue and are involved in regulatory mechanisms related to actin cytoskeleton and
398 intracellular calcium homeostasis, a mechanism central to vascular contraction. *iii*) We found
399 an important genetic overlap between FMD and blood pressure, not only for the associated
400 loci and genes but also globally at the GWAS level, but demonstrated that hypertension is not
401 driving the genetic association with FMD. *iv*) We reported shared genetic bases and
402 potentially biological mechanisms with some but not all cardiovascular and neurovascular
403 diseases, which is only partially driven by shared genetic basis with blood pressure.

404 The genetic investigation of FMD has been inconclusive for decades due to the lack of a clear
405 genetic model. Efforts to establish large cohorts of FMD patients to conduct well-powered
406 genetic studies are very recent and follow the increased awareness about its relatively high
407 prevalence (~3%) in asymptomatic individuals²¹. FMD patients are commonly middle-aged
408 women, long considered at low risk for the common cardiovascular diseases.

409 Our strategy combining single SNP and gene-based GWAS and TWAS in arterial tissues
410 identified three novel loci and several novel genes to contribute to FMD genetic risk. Most of
411 these loci were previously shown to be involved in multiple vascular diseases. *LRPI* is a risk

412 locus for pulse pressure²², migraine²³, aortic abdominal aneurysm²⁴, and was recently reported
413 for spontaneous coronary artery dissection^{25,26} involving the same risk allele for FMD that
414 correlates with higher gene expression. However, the opposite allele was reported to increase
415 the risk for MoyaMoya disease²⁷ and suggestively for CAD²⁸. LRP1 plays important roles in
416 multiple cellular processes relevant to FMD such as the remodelling of the extracellular
417 matrix and VSMCs migration²⁹. LRP1 function in VSMCs is mediated partly by the
418 modulation of calcium signalling, leading to deficient vasoconstriction in VSMC-specific
419 *Lrp1*-deficient mice³⁰.

420 Interestingly, two of the genes we identified are directly involved in intracellular calcium
421 homeostasis, a highly relevant molecular mechanism to vascular contractility and
422 vasodilation. *ATP2B1* encodes an ATP-dependent calcium channel specialized in the
423 exportation of calcium ions from the cytoplasm to the extracellular space. *ATP2B1* is a well-
424 established hypertension and blood pressure locus, where the same alleles increase the risk for
425 FMD and hypertension (**Figure 4**). Mice lacking *Atp2b1* specifically in VSMCs exhibit
426 hypertension, higher intracellular calcium levels and increased sensitivity to nifedipine, a
427 calcium channel blocker^{31,32}. On the other hand, *SLC24A3*, which we identified through the
428 TWAS analyses in tibial arteries to associate with FMD, encodes a transmembrane
429 sodium/potassium/calcium exchanger also involved in calcium homeostasis³³. The relevance
430 of impaired vasodilation and/or enhanced vasoconstriction in FMD pathogenesis is supported
431 by our recent study where we reported an enrichment among FMD patients for rare loss-of-
432 function mutations in the gene encoding the receptor for prostacyclin, a major vasodilator
433 hormone³⁴. In line with these findings, impaired dilation of arteries in response to sublingual
434 glyceryl trinitrate, a proxy for VSMC dysfunction, was reported in FMD patients, including in
435 arterial segments clinically unaffected by the disease³⁵.

436 The role of some novel genes in the pathogenesis of FMD is still unclear. The signal
437 transducer and activator of transcription 6 gene (*STAT6*) is a ubiquitous transcription factor
438 involved in intracellular processes linked to inflammation, although colocalization and eQTL
439 analyses privileged *LRP1* as causal in this locus. *GPD1* encodes a glycerol-3 phosphate
440 dehydrogenase 1 involved in lipid metabolism, which expression is detected at low levels in
441 arteries. In this locus, where effect estimates of associated variants were higher in multifocal
442 FMD and women, *LIMA1* and *ATF1* are two strong biological candidates. *LIMA1* role in
443 actin dynamics is compatible with a potential role in maintaining cell shape, a feature lost in
444 FMD affected VSMCs³⁶. A study described a rare frameshift variant in *LIMA1* from a family
445 with inherited low LDL cholesterol and resistance in diet induced hypercholesterolemia in
446 *Lima1* deficient mouse³⁷. While its specific role in arteries is not known, *ATF1* is a
447 transcriptional effector of the cyclic adenosine monophosphate pathway, which plays a key
448 role in the regulation of vascular tone³⁸.

449 Our study provides robust confirmation of the association with FMD of *PHACTR1*, a
450 pleiotropic locus that is involved in a large number of vascular diseases^{39,40}. The functional
451 annotation using open chromatin in vascular cells and arterial tissue, the colocalization
452 analyses, TWAS in arteries and eQTL results, including specifically in FMD patients, all
453 point to rs9349379 as a clear regulator of *PHACTR1*, the most likely causal gene in FMD, and
454 probably in the other vascular diseases as well. The previously suggested regulation of the
455 endothelin-1 gene (*EDNI*)³⁹ is not supported by our results, or those from consequent works
456 that used an identical approach of iPSC induced endothelial cells⁴¹ or measured endothelin-1
457 plasma levels in FMD patients and matched healthy controls⁴². On the other hand, the
458 phosphatase and actin-binding protein encoded by *PHACTR1* regulates actin stress fibre
459 assembly and cell motility⁴³, functions highly relevant to the cellular disorganization that
460 characterizes VSMCs in multifocal FMD affected arteries³⁶. Further investigation, especially

461 with *in vivo* models, are needed to more precisely define the function of *PHACTR1* in the
462 context of the genetic risk to a diverse panel of cardiovascular and neurovascular diseases.

463 Through genetic correlation analyses we were able to globally position the genetic basis of
464 FMD among the genetics of more commonly studied cardiovascular and neurovascular
465 diseases and traits. We showed that FMD shares a significant proportion of its genetic basis
466 with hypertension and blood pressure related traits, not only for the top associated loci and
467 genes but also genome-wide. FMD is often diagnosed in the context of hypertension, although
468 we have demonstrated that hypertension is not driving the genetic association with FMD in
469 the currently studied cohorts. Blood pressure regulation is highly complex and involves
470 multiple organs⁴⁴. The identification of several genes related to intracellular calcium
471 regulation, and the absence of genetic correlation between FMD and multiple renal function
472 traits, suggests that impaired regulation of vascular tone genetically drives the multiple
473 stenoses phenotype observed in FMD that results in increased blood pressure. Future
474 exploration of more common genetic loci between FMD and blood pressure will certainly
475 enlighten additional mechanisms and potentially point to specific therapeutic targets to be
476 privileged in FMD hypertensive patients.

477 We showed an expected positive genetic correlation between FMD and migraine, which is
478 reported by 25 to 69% of FMD patients^{4,8}, and cervical artery dissection, which occurs in the
479 same cerebrovascular beds affected in FMD (i.e. carotid and vertebral arteries). However, we
480 found little support for shared genetics with ischemic stroke subtypes despite FMD being
481 frequently diagnosed in the context of a stroke event. On the other hand, FMD seems to be
482 more genetically related to intracranial aneurysm and aneurysmal subarachnoid haemorrhage.
483 This type of stroke shares several clinical characteristics with FMD, mainly high proportion
484 of patients < 55 years, association with blood pressure and smoking, and a higher propensity
485 of women among patients⁴⁵. Finally, we observed an inverse association between FMD and

486 CAD/MI both for the top loci and genes, and globally when FMD association is conditioned
487 on systolic blood pressure. The elimination of the presence of atherosclerosis as the cause of
488 stenoses and aneurysms is required for FMD diagnosis, which may have influenced this
489 negative correlation with a disease where atherosclerosis is under-represented. FMD is a
490 disease afflicting young to middle-aged women, who are less prone to develop CAD and MI,
491 which predominantly afflict older men. Whether FMD patients are less likely to develop
492 CAD/MI later in life, compared to patients of similar clinical characteristics is not known.
493 Endogenous or exogenous female hormones are considered to be protective factors from
494 CAD/MI⁴⁶, but are suspected as a potential risk factor in FMD pathogenesis, given the high
495 proportion of women among patients (80 to 90%) and the age of diagnosis of FMD (on
496 average ~50 years)⁴. Oestrogens stimulate the release of vasodilator mediators such as nitric
497 oxide and prostacyclin and inhibit the potent vasoconstrictor endothelin-1⁴⁶. Our study did not
498 point to any direct link with sex hormone metabolism or regulation, except sex differences in
499 the level of expressions among women compared to men for *PHACTR1* and *SLC24A3*,
500 consistent with the direction of effects of FMD risk alleles. More knowledge about detailed
501 biological and physiological roles of both genes are needed to address potential consequences
502 on artery remodelling in sex and atherosclerosis dependent contexts.

503

504 In summary, in this first meta-analysis of GWAS for FMD, we report robustly associated loci
505 and genes and provide several new leads toward understanding biological mechanisms of
506 stenosis and dissection in young women in the absence of atherosclerosis. Further
507 investigation of the exact biological effects driven by these genes may shed light on the cause
508 of higher prevalence of FMD in women and provide insights into the shared genetic basis
509 between FMD and more common cardiovascular and neurovascular diseases.

510 REFERENCES

511

- 512 1. World Health, O. *World health statistics 2020: monitoring health for the SDGs,*
513 *sustainable development goals*, (World Health Organization, Geneva, 2020).
- 514 2. Plouin, P.F. *et al.* Fibromuscular dysplasia. *Orphanet J Rare Dis* **2**, 28 (2007).
- 515 3. Kiando, S.R. *et al.* PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular
516 Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. *PLoS Genet* **12**,
517 e1006367 (2016).
- 518 4. Gornik, H.L. *et al.* First International Consensus on the diagnosis and management of
519 fibromuscular dysplasia. *Vasc Med* **24**, 164-189 (2019).
- 520 5. Cordonnier, C. *et al.* Stroke in women - from evidence to inequalities. *Nat Rev Neurol*
521 **13**, 521-532 (2017).
- 522 6. Haider, A. *et al.* Sex and gender in cardiovascular medicine: presentation and
523 outcomes of acute coronary syndrome. *Eur Heart J* **41**, 1328-1336 (2020).
- 524 7. Pappaccogli, M. *et al.* THE EUROPEAN/INTERNATIONAL FIBROMUSCULAR
525 DYSPLASIA REGISTRY AND INITIATIVE (FEIRI)- CLINICAL PHENOTYPES
526 AND THEIR PREDICTORS BASED ON A COHORT OF ONE THOUSAND
527 PATIENTS. *Cardiovasc Res* (2020).
- 528 8. Plouin, P.F. *et al.* High Prevalence of Multiple Arterial Bed Lesions in Patients With
529 Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and
530 Cervical Artery Dysplasia). *Hypertension* **70**, 652-658 (2017).
- 531 9. Olin, J.W. *et al.* The United States Registry for Fibromuscular Dysplasia: results in the
532 first 447 patients. *Circulation* **125**, 3182-90 (2012).
- 533 10. Shivapour, D.M., Erwin, P. & Kim, E. Epidemiology of fibromuscular dysplasia: A
534 review of the literature. *Vasc Med* **21**, 376-81 (2016).
- 535 11. Hayes, S.N. *et al.* Spontaneous Coronary Artery Dissection: Current State of the
536 Science: A Scientific Statement From the American Heart Association. *Circulation*
537 **137**, e523-e557 (2018).
- 538 12. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
- 539 13. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: generalized
540 gene-set analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).
- 541 14. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
542 and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 543 15. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
544 studies. *Nat Genet* **48**, 245-52 (2016).
- 545 16. Kalluri, A.S. *et al.* Single-Cell Analysis of the Normal Mouse Aorta Reveals
546 Functionally Distinct Endothelial Cell Populations. *Circulation* **140**, 147-163 (2019).
- 547 17. Miller, C.L. *et al.* Integrative functional genomics identifies regulatory mechanisms at
548 coronary artery disease loci. *Nat Commun* **7**, 12092 (2016).
- 549 18. Schmidt, E.M. *et al.* GREGOR: evaluating global enrichment of trait-associated
550 variants in epigenomic features using a systematic, data-driven approach.
551 *Bioinformatics* **31**, 2601-6 (2015).
- 552 19. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
553 associated with blood pressure traits. *Nat Genet* **50**, 1412-1425 (2018).
- 554 20. Ni, G., Moser, G., Wray, N.R. & Lee, S.H. Estimation of Genetic Correlation via
555 Linkage Disequilibrium Score Regression and Genomic Restricted Maximum
556 Likelihood. *Am J Hum Genet* **102**, 1185-1194 (2018).

- 557 21. Hendricks, N.J. *et al.* Is fibromuscular dysplasia underdiagnosed? A comparison of the
558 prevalence of FMD seen in CORAL trial participants versus a single institution
559 population of renal donor candidates. *Vasc Med* **19**, 363-7 (2014).
- 560 22. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over
561 750,000 individuals. *Nat Genet* **51**, 51-62 (2019).
- 562 23. Gormley, P. *et al.* Meta-analysis of 375,000 individuals identifies 38 susceptibility
563 loci for migraine. *Nat Genet* **48**, 856-66 (2016).
- 564 24. Bown, M.J. *et al.* Abdominal aortic aneurysm is associated with a variant in low-
565 density lipoprotein receptor-related protein 1. *Am J Hum Genet* **89**, 619-27 (2011).
- 566 25. Turley, T.N. *et al.* Identification of Susceptibility Loci for Spontaneous Coronary
567 Artery Dissection. *JAMA Cardiol* **5**, 1-10 (2020).
- 568 26. Saw, J. *et al.* Chromosome 1q21.2 and additional loci influence risk of spontaneous
569 coronary artery dissection and myocardial infarction. *Nat Commun* **11**, 4432 (2020).
- 570 27. Duan, L. *et al.* Novel Susceptibility Loci for Moyamoya Disease Revealed by a
571 Genome-Wide Association Study. *Stroke* **49**, 11-18 (2018).
- 572 28. van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an
573 Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res*
574 **122**, 433-443 (2018).
- 575 29. Bres, E.E. & Faissner, A. Low Density Receptor-Related Protein 1 Interactions With
576 the Extracellular Matrix: More Than Meets the Eye. *Front Cell Dev Biol* **7**, 31 (2019).
- 577 30. Au, D.T. *et al.* LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1)
578 Regulates Smooth Muscle Contractility by Modulating Ca(2+) Signaling and
579 Expression of Cytoskeleton-Related Proteins. *Arterioscler Thromb Vasc Biol* **38**,
580 2651-2664 (2018).
- 581 31. Kobayashi, Y. *et al.* Mice lacking hypertension candidate gene ATP2B1 in vascular
582 smooth muscle cells show significant blood pressure elevation. *Hypertension* **59**, 854-
583 60 (2012).
- 584 32. Okuyama, Y. *et al.* The effects of anti-hypertensive drugs and the mechanism of
585 hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice.
586 *Hypertens Res* **41**, 80-87 (2018).
- 587 33. Yang, H. *et al.* NCKX3 was compensated by calcium transporting genes and bone
588 resorption in a NCKX3 KO mouse model. *Mol Cell Endocrinol* **454**, 93-102 (2017).
- 589 34. Georges, A. *et al.* Rare Loss-of-function Mutations of PTGIR are enriched in
590 Fibromuscular Dysplasia. *Cardiovasc Res* (2020).
- 591 35. Bruno, R.M. *et al.* Deep Vascular Phenotyping in Patients With Renal Multifocal
592 Fibromuscular Dysplasia. *Hypertension* **73**, 371-378 (2019).
- 593 36. Stanley, J.C., Gewertz, B.L., Bove, E.L., Sottiurai, V. & Fry, W.J. Arterial
594 fibrodysplasia. Histopathologic character and current etiologic concepts. *Arch Surg*
595 **110**, 561-6 (1975).
- 596 37. Zhang, Y.Y. *et al.* A LIMA1 variant promotes low plasma LDL cholesterol and
597 decreases intestinal cholesterol absorption. *Science* **360**, 1087-1092 (2018).
- 598 38. Morgado, M., Cairrão, E., Santos-Silva, A.J. & Verde, I. Cyclic nucleotide-dependent
599 relaxation pathways in vascular smooth muscle. *Cell Mol Life Sci* **69**, 247-66 (2012).
- 600 39. Gupta, R.M. *et al.* A Genetic Variant Associated with Five Vascular Diseases Is a
601 Distal Regulator of Endothelin-1 Gene Expression. *Cell* **170**, 522-533.e15 (2017).
- 602 40. Adlam, D. *et al.* Association of the PHACTR1/EDN1 Genetic Locus With
603 Spontaneous Coronary Artery Dissection. *J Am Coll Cardiol* **73**, 58-66 (2019).
- 604 41. Wang, X. & Musunuru, K. Confirmation of Causal rs9349379- PHACTR1 Expression
605 Quantitative Trait Locus in Human-Induced Pluripotent Stem Cell Endothelial Cells.
606 *Circ Genom Precis Med* **11**, e002327 (2018).

- 607 42. Olin, J.W. *et al.* A Plasma Proteogenomic Signature for Fibromuscular Dysplasia.
608 *Cardiovasc Res* (2019).
- 609 43. Wiezlak, M. *et al.* G-actin regulates the shuttling and PP1 binding of the RPEL protein
610 Phactr1 to control actomyosin assembly. *J Cell Sci* **125**, 5860-72 (2012).
- 611 44. Beevers, G., Lip, G.Y. & O'Brien, E. ABC of hypertension: The pathophysiology of
612 hypertension. *Bmj* **322**, 912-6 (2001).
- 613 45. Etminan, N. *et al.* Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage
614 According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the
615 Population: A Systematic Review and Meta-analysis. *JAMA Neurol* **76**, 588-597
616 (2019).
- 617 46. Perez-Lopez, F.R., Larrad-Mur, L., Kallen, A., Chedraui, P. & Taylor, H.S. Gender
618 differences in cardiovascular disease: hormonal and biochemical influences. *Reprod*
619 *Sci* **17**, 511-31 (2010).
- 620 47. Vascular factors and risk of dementia: design of the Three-City Study and baseline
621 characteristics of the study population. *Neuroepidemiology* **22**, 316-25 (2003).
- 622 48. Ye, Z., Kallou, F.S., Dalenberg, A.K. & Kullo, I.J. An electronic medical record-
623 linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular
624 disease. *Glob Cardiol Sci Pract* **2013**, 82-90 (2013).
- 625 49. Dobrowolski, P. *et al.* Echocardiographic assessment of left ventricular morphology
626 and function in patients with fibromuscular dysplasia: the ARCADIA-POL study. *J*
627 *Hypertens* **36**, 1318-1325 (2018).
- 628 50. Drygas, W. *et al.* Multi-centre National Population Health Examination Survey
629 (WOBASZ II study): assumptions, methods, and implementation. *Kardiol Pol* **74**,
630 681-90 (2016).
- 631 51. Fritsche, L.G. *et al.* Association of Polygenic Risk Scores for Multiple Cancers in a
632 Phenome-wide Study: Results from The Michigan Genomics Initiative. *Am J Hum*
633 *Genet* **102**, 1048-1061 (2018).
- 634 52. Rietzschel, E.R. *et al.* Rationale, design, methods and baseline characteristics of the
635 Asklepios Study. *Eur J Cardiovasc Prev Rehabil* **14**, 179-91 (2007).
- 636 53. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium
637 panel. *Nat Genet* **48**, 1443-1448 (2016).
- 638 54. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet*
639 **48**, 1284-1287 (2016).
- 640 55. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and
641 richer datasets. *Gigascience* **4**, 7 (2015).
- 642 56. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of
643 genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
- 644 57. Battle, A., Brown, C.D., Engelhardt, B.E. & Montgomery, S.B. Genetic effects on
645 gene expression across human tissues. *Nature* **550**, 204-213 (2017).
- 646 58. Liu, B., Gludemans, M.J., Rao, A.S., Ingelsson, E. & Montgomery, S.B. Abundant
647 associations with gene expression complicate GWAS follow-up. *Nat Genet* **51**, 768-
648 769 (2019).
- 649 59. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
650 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 651 60. Corces, M.R. *et al.* An improved ATAC-seq protocol reduces background and enables
652 interrogation of frozen tissues. *Nat Methods* **14**, 959-962 (2017).
- 653 61. Freese, N.H., Norris, D.C. & Loraine, A.E. Integrated genome browser: visual
654 analytics platform for genomics. *Bioinformatics* **32**, 2089-95 (2016).

- 655 62. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide
656 association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**,
657 D1005-d1012 (2019).
- 658 63. Debette, S. *et al.* Common variation in PHACTR1 is associated with susceptibility to
659 cervical artery dissection. *Nat Genet* **47**, 78-83 (2015).
- 660 64. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects
661 identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524-537
662 (2018).
- 663 65. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from
664 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5 (2015).
- 665 66. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred
666 from GWAS summary data. *Nat Commun* **9**, 224 (2018).
- 667

668 **Ethical Statement**

669 All studies involved individual written informed consent from all participants and received
670 approval from respective local ethics committee. The ARCADIA study was approved by the
671 « Comité de Protection des Personnes » CPP Ile-de-France II- ID RCB: 2009-A00288-49.
672 The 3 cities protocol was approved by “comité consultatif de protection des personnes dans la
673 recherche biomédicale Bicêtre Hôpital Bicêtre n°99-28 CCPPRB approved 10/06/99,
674 11/03/2003 and 17/03/2006. ARCADIA-Pol study was approved by Local Ethics Committee,
675 Institute of Cardiology, IK-NPIA-0021017/1482/17. The WOBASZ II Project was accepted
676 by the Field Bioethics Committee of the Institute of Cardiology in Warsaw (IK-NP-0021-
677 69/1344/12). All centres included in FEIRI received approval from the respective local/
678 national ethics committees. ASKLEPIOS study was approved by the ethical committee of the
679 Ghent University Hospital, Belgium. The DEFINE case control study is a Mount Sinai
680 Health System Study ID: HSM# 13-00575 / GCO# 13-1118. The Mayo Clinic case control
681 study was approved by Mayo Clinic IRB #08-008355. The UM case control study was
682 approved by University of Michigan IRB #HUM00044507, #HUM00112101 and Cleveland
683 Clinic IRB approval #10-318

684

685

686 **Acknowledgements**

687 We thank all patients who participated in these studies. We thank Dr Antoine Chédid for
688 collecting and managing clinical data of patients in ARCADIA protocol. We thank Patrick
689 Bruneval for his scientific input and exchanges about arterial pathology in FMD. This study
690 contributes to the IdEx Université de Paris ANR-18-IDEX-0001. This work has benefited
691 from the facilities and expertise of the high throughput sequencing core facility of I2BC
692 (Centre de Recherche de Gif – <http://www.i2bc.paris-saclay.fr/>). ARCADIA-Pol investigators
693 thank Ewa Rudolf, Elzbieta Pazio and Małgorzata Lewandowska, who were responsible for
694 all administrative work. The Steering Committee of the WOBASZ study expresses special
695 thanks for participation in the implementation of the study to: all their co-workers from
696 research teams at six academic centres, to nurses, doctors, and analysts from field research
697 centres located in 16 voivodeships. We acknowledge the Spanish National Cancer Research
698 Centre (CNIO), in the Human Genotyping lab, a member of CeGen where genotyping was
699 performed for part of the cohorts studied. We thank the participants of the study and the
700 Fibromuscular Dysplasia Society of America for facilitating the enrolment of subjects at their
701 annual meetings. We thank the Frankel Cardiovascular Center and M-BRISC program for
702 their support and the University of Michigan Advanced Genomics Core where MGI study
703 performed genotyping. The authors acknowledge the University of Michigan Precision Health
704 Initiative and Medical School Central Biorepository for providing biospecimen storage,
705 management, processing and distribution services and the Center for Statistical Genetics in
706 the Department of Biostatistics at the School of Public Health for genotype data management
707 in support of this research. Some illustrations were designed by macrovector / Freepik.

708

709

710

711 **Funding**

712 This study was supported by the European Research Council grant (ERC-Stg-ROSALIND-
713 716628) to NB-N and National Institute of Health grant (R01 HL139672) to SKG. The
714 ARCADIA study was sponsored by the Assistance Publique-Hôpitaux de Paris and funded by
715 a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique
716 2009, AOM 08192) and the Fondation de Recherche sur l'Hypertension Artérielle.
717 Genotyping of French study was supported by the French research agency (ANR-13-JSV1-
718 0002) to NB-N. The genotyping of controls from the Three-City Study (3C) was supported by
719 the non-profit organization Fondation Alzheimer (Paris, France) to PA. ARCADIA-Pol study
720 was supported by the grant no. 2.40/III/19 of Institute of Cardiology, Poland. The WOBASZ
721 II Project was financed from the resources at the disposal of the Polish Minister of Health
722 within the framework of the "National Program of Equalization and Accessibility to
723 Cardiovascular Disease Prevention and Treatment for 2010-2012. MV benefited from Fonds
724 de la Recherche Scientifique - FNRS Grant T.0247.19, Belgium. The Spanish National
725 Cancer Research Centre (CNIO), in the Human Genotyping lab, a member of CeGen
726 Biomolecular resources platform (PRB3), is supported by grant PT17 /0019, of the PE I+D+i
727 2013-2016, funded by *Instituto de Salud Carlos III* and a European regional development
728 fund (ERDF). DEFINE-FMD is supported by NIH grant 1R01HL148167-01A1 to JCK. BAS
729 is supported by the Mayo Clinic Clinician-Investigator Training Program. IJK is additionally
730 supported by NIH grant K24HL137010. The UM study is supported by NHLBI/NIH (R01
731 HL139672, R01 HL122684), the University of Michigan Taubman Institute, Frankel
732 Cardiovascular Center. S.K.G. is supported by R01HL139672, R01HL122684, and
733 R01HL086694. The Michigan Genomics Initiative was supported by the University of
734 Michigan Precision Health Initiative. The Cleveland Clinic Biorepository was supported by
735 CTSA 1UL1RR024989. The Cleveland Clinic FMD Biorepository has been supported in part

736 by the National Institutes of Health, National Center for Research Resources, CTSA
737 1UL1RR024989, Cleveland, Ohio. YR received funding from the European Research Council
738 (ERC) under the European Union's Horizon 2020 research and innovation program (grant
739 agreement No. 852173). Intracranial aneurysm working group acknowledges the support from
740 the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch
741 Heart Foundation, CVON2015-08 ERASE.

742

743 **Authors contributions**

744 Writing and editing the manuscript: AG, T-EB, SKG, NB-N. Study design / conception: AG,
745 T-EB, SKG, NB-N. Genotyping experiments: J-FD, DD, KLH, MV. Sample /phenotype
746 contribution: LA, CAB, CMB, DMC, HG, SKG, PDL, NF-M, DK-D, JZL, AL, MP, AP, WS,
747 JCS, MZ, XZ, SZ, FEIRI Consortium, PA, MLdB, SD, PD, WD, HLG, JWO, JP, ERR, EW-
748 C, AJ, IJK, MA, XJ, AP, JCK. GWAS analyses: M-LY, T-EB, MB, OD, SRK, LM, BAS, SS,
749 MY, XZ, JZL. Gene-based and LD score analyses: T-EB. Functional annotation experiments:
750 AG, SK, LL. TWAS, in silico functional annotations: AG. eQTL colocalization analyses: M-
751 LY. Data for IA/SAH genetic correlation: MB, ISGC intracranial working group, YR. Data
752 for stroke genetic correlation: MEGASTROKE. eQTL data and analysis in FMD and control
753 fibroblasts: LM, Vd'E, JCK.

754

755 **Competing Interest**

756 HLG, SKG, JO, and JCS are non-compensated members of the Medical Advisory Board of
757 the FMD Society of America (FMDSA). SKG is a non-compensated member of the Scientific
758 Advisory Board of SCAD Alliance. Both are non-profit organizations.

759

760

761 **Data availability**

762 Data will be made available after acceptance of the article.

763

764 **Figure legends**

765 **Figure 1. SNP-based, gene-based and transcriptome wide association analyses**

766 **a:** Manhattan plot representation of SNP-based association analysis in multifocal FMD. $-\log_{10}$
767 of association P -value is represented on the y-axis, genomic coordinates on the x-axis. Name
768 of lead SNPs with P -value $\leq 5 \times 10^{-8}$ are indicated. **b-c:** Manhattan plot representation of **b:**
769 gene-based association analysis in multifocal FMD; **c:** Transcriptome-wide association
770 analysis (TWAS) in FMD with tibial artery gene expression models. $-\log_{10}$ of association P -
771 value is represented on the y-axis, genomic coordinates on the x-axis. Name of genes with
772 Bonferroni corrected P -value ≤ 0.05 are indicated. **d:** Volcano plot representation of FMD
773 TWAS. TWAS Z-score is represented on the x-axis, $-\log_{10}$ of TWAS P -value on the y-axis.
774 Dashed line represents the threshold for significance adjusted for multiple testing. Name of
775 genes with Bonferroni adjusted P -value < 0.05 are indicated.

776

777 **Figure 2. Tissue-wide eQTL signals near FMD loci**

778 **a:** Heatmap representation of eQTL signals at FMD loci. GTEx v8 database was queried for
779 significant eQTLs using the lead variant rsID number. All genes identified as positive eQTL
780 in at least one tissue were selected to calculate eQTL associations in all tissues available in
781 this database. The negative logarithm ($-\log_{10}$) of the eQTL association P -values are
782 represented in a blue-red colour scale. **b, d, f, h:** Violin plots representing normalized
783 expression of *PHACTR1* (**b**), *LRPI* (**d**), *ATP2B1* (**f**) and *ATF1* (**h**) by genotype of lead SNPs
784 in tibial artery (**b, d, f**) and aortic tissue (**h**). Plots illustrate the best eQTL association in
785 arterial tissue for the lead SNP at each locus. eQTL P -value is indicated. **c, e, g, i:**

786 Colocalization plot of FMD association (x-axis, log scale of P -value) with arterial eQTL
787 association (y-axis, log-scale of P -value) at each locus. Dot colour represents the LD r^2 with
788 the lead variant in 1000G European samples. FMD lead variant is highlighted (Diamond
789 shape, purple). Approximate Bayes Factor Posterior Probability ($PP.abf$) for the two traits to
790 share a common causal variant is indicated.

791

792 **Figure 3. Characterization of open chromatin regions in artery derived primary cells**

793 **a:** Number of reads (grey) and number of peaks (orange) obtained for ATAC-Seq libraries
794 from primary cells and artery tissue. HctASMC: human carotid artery smooth muscle cells,
795 HCASMC: human coronary artery smooth muscle cells, HctAEC: human carotid artery
796 endothelial cells, HCAEC: human coronary artery endothelial cells, HDF: human dermal
797 fibroblasts, HCF: human cardiac fibroblasts, NCA: normal coronary arteries. NCA ATAC-
798 Seq libraries were generated and sequenced by Miller and colleagues¹⁷ and raw reads were
799 retrieved from the sequence read archive (<https://www.ncbi.nlm.nih.gov/sra>). **b:** Heatmap
800 representation of Spearman correlation and hierarchical clustering of ATAC-Seq datasets.
801 The three main clusters correspond to VSMCs/fibroblasts, ECs and arteries, and are identified
802 on the dendrogram. Rho correlation coefficient is represented by a red-blue colour scale and
803 indicated in each box. **c:** Principal component analysis of ATAC-Seq datasets. Upper panel
804 shows the position of samples with respect to first two principal components. Lower panel
805 indicates the eigenvalues of the first 10 principal components. **d:** Representation of FMD
806 SNPs fold-enrichment (x-axis) and enrichment P -value (log scale, y-axis) among indicated
807 ATAC-Seq samples. The overlap of FMD lead SNPs ($P < 10^{-4}$ for the lead SNP) and proxies
808 ($r^2 \geq 0.7$) with ATAC-Seq peaks was compared to 500 pools of randomized matched SNPs to
809 calculate the indicated enrichments. Lower panel shows the average fold enrichment in each
810 group of samples. **e:** Bubble graph representing the clustering of enriched ($P < 10^{-3}$) gene

811 ontology (GO) Biological Processes terms among genes (N=1425) located in the vicinity of
812 artery-specific open chromatin regions (regions enriched over VSMCs and ECs). Similar
813 terms were grouped using REVIGO webserver (<http://revigo.irb.hr/>) with “Medium” setting.
814 Bubble size indicates the number of enriched GO terms in each group. Bubble colour
815 indicates the *P*-value of the most enriched term in each group. X- and Y-axes represent
816 arbitrary semantic coordinates. **f**: Bar plot representing the enrichment score of the top 5
817 clusters obtained by Functional Annotation Clustering of the indicated 1425 genes using
818 DAVID webserver (<https://david.ncifcrf.gov/home.jsp>). Most enriched term is indicated for
819 each cluster.

820

821 **Figure 4. Visualization of potential causal variants genes at FMD-associated loci**

822 **a, c, e, g**: LocusZoom representation of FMD associated loci (**a**: *PHACTR1* locus, **c**: *LRP1*
823 locus, **e**: *ATP2B1* locus, **g**: *LIMAI* locus). Dot colour indicates LD of each variant with the
824 highlighted lead variant (purple diamond). Position and rsID of putative causal variants are
825 indicated. **b, d, f, h**: Genome browser visualization of ATAC-Seq/Histone ChIP read densities
826 (in reads/million, r.p.m.) in the regions surrounding putative causal variants. **b**: *PHACTR1*
827 locus. **d**: *LRP1* locus. **f**: *ATP2B1* locus. **h**: *LIMAI* locus. Grey line highlights variant position.

828

829 **Figure 5. Pairwise trait colocalization of FMD associations**

830 **a**: Associations of FMD loci with other vascular diseases. Variants in LD ($r^2 > 0.5$) with the
831 lead SNP were used to query GWAS catalog database (accessed on August 5th 2020), UK
832 BioBank GWAS traits and specific meta-analysis of GWAS for CAD/MI, stroke, blood
833 pressure and intracranial aneurysms. Two independent lead SNPs were retained for *SLC24A3*
834 locus. Overlaps are reported for the following traits/diseases: hypertension (HTN), pulse
835 pressure (PP), systolic blood pressure (SBP), diastolic blood pressure (DBP), migraine (Mig),

836 cervical artery dissection (CeAD), spontaneous coronary artery dissection (SCAD),
837 abdominal aortic aneurysm (AAA), MoyaMoya disease (MD), coronary artery calcification
838 (CAC), coronary artery disease (CAD) and myocardial infarction (MI). Large bubbles
839 indicate association below genome-wide significance for the corresponding trait ($P < 5 \times 10^{-8}$),
840 smaller bubbles correspond to suggestive signals ($P < 1 \times 10^{-5}$). Red colour indicates same
841 direction effects of risk alleles compared to the association with FMD, blue colour opposite
842 direction associations. **b:** Heatmap representation of TWAS Z-Score for FMD associated
843 genes. TWAS was performed with tibial artery gene expression models for the indicated traits
844 or diseases (x-axis). Z-scores are shown for all FMD associated genes in the gene-based and
845 TWAS analyses (y-axis).

846

847 **Figure 6. Genetic correlations between FMD and other traits and diseases**

848 **a:** Genetic correlation obtained using LD Score analyses between FMD and vascular diseases
849 and traits. HTN: hypertension, CAD: coronary artery disease, MI: myocardial infarction, AS:
850 any stroke, AIS: any ischemic stroke, LAS: large artery stroke, CES: cardioembolic stroke,
851 SVS: small vessel stroke, IA: intracranial aneurysm, all forms, SAH: aneurysmal
852 subarachnoid haemorrhage, i.e. ruptured intracranial aneurysm, uIA: unruptured intracranial
853 aneurysm. **b:** Genetic correlation obtained using LD Score analyses between FMD and
854 vascular diseases and metabolic traits. HDL: high density lipoprotein, LDL: low density
855 lipoprotein, TC: total cholesterol, TG: triglycerides, ApoA: apolipoprotein A, ApoB:
856 apolipoprotein B, eGFR: estimated glomerular filtration rate (calculated with creatinine or
857 cystatin), UACR: urine albumin to creatinine ratio, BUN: blood urea nitrogen, CRP: C-
858 reactive protein. **c, d:** Genetic correlation results after FMD genetic association statistics was
859 conditioned on systolic blood pressure. *: P -value is below the multiple testing threshold for
860 significance (1.6×10^{-3} for 31 tests).

861 **METHODS**

862 **Patients and control populations**

863 The meta-analysis included participants of European ancestry from six studies:
864 ARCADIA⁸/3C⁴⁷ GWAS, Mayo Vascular Disease Biorepository⁴⁸, DEFINE-FMD study⁴²,
865 ARCADIA-POL⁴⁹/WOBASZII⁵⁰ study, University of Michigan/Cleveland Clinic (UM)
866 study^{26,51} and FEIRI⁷/ASKLEPIOS⁵² study. FMD patients presented similar clinical
867 characteristics (**Supplementary Table S1**) and homogeneous diagnosis, exclusion and
868 inclusion criteria. Detailed description of the participating cohorts is available in the
869 supplementary appendix.

870

871 **Genome-wide association analyses and meta-analysis**

872 Details on genotyping, variant calling for each cohort and pre-imputation quality control in
873 each study are listed in **Supplementary Table S12**. In brief, genotyping was performed using
874 commercially available arrays. To increase the number of tested SNPs and the overlap of
875 variants available for analysis between different arrays, all European ancestry cohorts imputed
876 genotypes to the most current HRC v1.1 reference panel⁵³ on the Michigan Imputation
877 Server⁵⁴. GWAS was conducted in each study under an additive genetic model using PLINK
878 v2.0⁵⁵. Models were adjusted for population structure using the first five principal
879 components, sex (except in the women-only analyses) and study specific genomic control.
880 Prior to meta-analysis, we removed single nucleotide polymorphisms (SNPs) with low minor
881 allele frequencies (MAF) ($< \square 0.01$), low imputation quality ($r^2 < 0.8$ for French and UM
882 studies and $r^2 < \square 0.3$ for the others studies), and deviations from Hardy-Weinberg equilibrium
883 ($P \square < \square 10^{-\square 5}$). A total of 6,477,066 variants met these criteria and were kept in the final
884 results.

885 Association results were combined using an inverse variance weighted fixed-effects meta-
886 analysis in METAL software⁵⁶, with correction for genomic control. Heterogeneity was
887 assessed using the I^2 metric from the complete study-level meta-analysis. Between-study
888 heterogeneity was tested using the Cochran Q statistic and considered significant at $P \leq 10^{-3}$.
889 Genome-wide significance threshold was set at the level of $P = 5.0 \times 10^{-8}$.
890 LocusZoom (<http://locuszoom.org/>) was used to provide regional visualization of results.

891 **eQTL and colocalization analyses**

892 We queried GTEx database (v8 release)⁵⁷ with rsID of lead variants at FMD loci in arterial
893 tissues for major associated genes (permutations q-value<0.05). For each identified gene,
894 variant-gene association was queried in all tissues using “eQTL calculator” function on GTEx
895 website (<https://gtexportal.org/home/>). Uncharacterized non-coding transcripts were excluded
896 from the analysis. For colocalization, three arterial samples (aorta, coronary, tibial) from
897 GTEx were pooled at each locus to compare with the FMD GWAS meta-analysis result and
898 the multifocal FMD GWAS meta-analysis result. We generated colocalization plots using
899 locuscompareR package⁵⁸ and Bayesian posterior probability was calculated using coloc.abf
900 function in R coloc package⁵⁹. The eQTL association results from coronary, tibial and aorta
901 arterial tissues were all retrieved for each transcript at each locus for Bayesian posterior
902 probability analysis, and the minimal P -values across these three tissues for each locus were
903 taken for generating the colocalization plots.

904

905 **Gene-based and transcriptome-wide association analyses**

906 Gene based association was conducted using the MAGMA tool¹³, implemented in the FUMA
907 platform¹⁴. Locations of protein-coding genes were defined as the regions from transcription
908 start site to transcription stop site (default option in MAGMA). TWAS was performed using
909 FUSION R/python package¹⁵. Gene expression models were precomputed from GTEx data

910 (v7 release) and were provided by the authors. Only genes with heritability P -value < 0.01
911 were used in the analysis. Uncharacterized non-coding transcripts were excluded from the
912 analysis. Both tools used linkage disequilibrium information from the European panel of the
913 1000 Genomes phase 3. Bonferroni multiple testing correction was applied using the p .adjust
914 function in R (v 3.6.1).

915

916 **Primary cell culture and ATAC-Seq experiments**

917 With the exception of the dermal fibroblast cell lines obtained under the DEFINE-FMD
918 protocol, other primary cells were purchased from Cell Applications (San Diego, CA) except
919 HDF (ATCC, Manassas, VA) and cultured with 5% CO₂ in a 37°C incubator following
920 manufacturer's instructions. VSMC cells were grown in DMEM supplemented with 5% FBS,
921 Insulin (5µg/mL), EGF (0.5ng/mL), bFGF (2ng/mL) and antibiotics. Cells were at passage 5
922 (HDF, HCF, HCtAEC, HCAEC) or 6 (HCtASMC, HCASMC) for ATAC-Seq analyses.
923 ATAC-Seq was performed following the Omni-ATAC protocol described previously⁶⁰.
924 Detailed description of ATAC-Seq experiments and analyses is in the supplementary
925 appendix.

926

927 **Annotation with epigenomic data**

928 We computed the overlap of variant with open chromatin regions (narrowpeak from MACS2
929 output + 100bp on each side) and histone-ChIP peaks using bedtools (v2.29.0) annotate
930 function. Full list of peak files used is available in **Supplementary Table S13**. Analysis of
931 SNP enrichment among ATAC-Seq peaks was performed using GREGOR¹⁸. The lead SNPs
932 from loci associated with P -value $< 10^{-4}$ were used as reference for FMD-associated SNPs.
933 We included in the analysis SNPs in LD with lead SNPs ($r^2 \geq 0.7$ in the European subset of the

934 1000 Genomes phase 3 reference panel). We used Integrated Genome Browser (IGB, v9.1.4)
935 to visualize read density profiles and peak positions in the context of human genome⁶¹.

936

937 **Overlap between FMD loci and other traits and diseases**

938 We queried the GWAS catalog database⁶², UK Biobank GWAS summary statistics made
939 publicly available by the Neale lab at the Broad Institute (<http://www.nealelab.is/uk-biobank>)
940 and GWAS meta-analyses on blood pressure¹⁹, spontaneous coronary artery dissection²⁵,
941 cervical artery dissection⁶³, CAD/MI²⁸, IA/uIA/SAH (Bakker *et al.*, *Nature Genetics*, in press,
942 pre-publication access) and Stroke⁶⁴ with FMD lead SNPs and LD proxies ($r^2 \geq 0.5$ in the
943 European panel of the 1000 Genomes phase 3). We reported vascular phenotypes with at least
944 one variant with genome-wide ($P < 5 \times 10^{-8}$) or suggestive ($P < 10^{-5}$) association. Colocalization
945 plots were generated using locuscompareR package⁵⁸. Comparative TWAS in FMD and other
946 traits was performed using HapMap filtered summary statistics (see below).

947

948 **Genetic correlation analyses**

949 We used LD score regression to estimate the genetic correlation between FMD and other
950 diseases and traits⁶⁵. Summary statistics were acquired from the respective consortia and are
951 detailed in **Supplementary Table S14**. For each trait, we filtered the summary statistics to
952 the subset of HapMap 3 SNPs to decrease the potential for bias due to poor imputation
953 quality. Correlation analyses were restricted to summary statistics from European ancestry
954 meta-analyses. We used the European LD-score files calculated from the 1000G reference
955 panel and provided by the developers. A $P < 1.6 \times 10^{-3}$, corresponding to adjustment for 31
956 independent phenotypes was considered significant. All analyses were performed with the
957 ldsc package (v1.0.1, <https://github.com/bulik/ldsc/>). We conditioned FMD association on
958 systolic blood pressure genetic association using multi-trait-based conditional and joint

959 analysis (mtCOJO) tool from GCTA pipeline⁶⁶. The resulting summary statistics were then
960 used to calculate genetic correlation between FMD, conditioned on systolic blood pressure,
961 and the previous traits.

962 **Table 1: FMD associated variants in SNP association analyses**

963

964 Meta-analysis was performed using inverse variance-weighted method. Heterogeneity between cohorts was tested using Cochran's Q statistics
 965 and was not significant. Chr: chromosome, EA: effect allele, EAF: effect allele frequency, OR: odds ratio

966

967

Lead Variant						All FMD		Multifocal FMD		Women FMD	
						1962 cases 7100 controls		1578 cases 7100 controls		1715 cases 5724 controls	
rsID	Chr	Position (hg19)	EA	EAF	Locus	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
rs9349379	6	12903957	A	0.63	<i>PHACTR1</i>	1.39 (1.28 - 1.51)	2.0×10 ⁻¹⁴	1.44 (1.31 - 1.57)	5.2×10 ⁻¹⁵	1.43 (1.30 - 1.56)	1.3×10 ⁻¹⁴
rs11172113	12	57527283	T	0.62	<i>LRP1</i>	1.31 (1.20 - 1.43)	2.6×10 ⁻¹⁰	1.34 (1.22 - 1.46)	2.0×10 ⁻¹⁰	1.32 (1.20 - 1.44)	1.5×10 ⁻⁹
rs17249754	12	90060586	G	0.84	<i>ATP2B1</i>	1.41 (1.26 - 1.58)	5.9×10 ⁻⁹	1.43 (1.26 - 1.62)	1.7×10 ⁻⁸	1.44 (1.27 - 1.63)	8.1×10 ⁻⁹
rs6580732	12	50646279	T	0.45	<i>LIMA1</i>	1.24 (1.14 - 1.34)	1.4×10 ⁻⁷	1.30 (1.19 - 1.41)	2.2×10 ⁻⁹	1.29 (1.18 - 1.40)	7.4×10 ⁻⁹

968 **Table 2. FMD associated genes in gene-based and transcriptome-wide association analyses**

969 The table shows *P*-values (*P*) of gene-based association calculated with MAGMA, uncorrected and corrected for multiple testing, and *p*-values
 970 and *Z*-scores (*Z*) of transcriptome-wide association based on gene-expression models from GTEx in tibial artery and GWAS in all FMD. All
 971 genes with Bonferroni corrected *P*-value below 0.05 in at least one condition are reported and the condition where the gene association reaches
 972 adjusted significance are highlighted in bold. Lead SNP is the one with the lowest *P*-value in GWAS in all FMD.

973 Best *P*: lowest *P*-value of the lead SNP in the three GWAS (all FMD cases, multifocal FMD or women) Chr: Chromosome, Bonf. : Bonferroni
 974 corrected *P*-value, N/A: not available

975
 976

Locus information		Gene information				Gene-based association						TWAS	
						All		Multifocal		Women		Tibial Arteries	
Lead SNP	Best <i>P</i>	Gene	Chr	Start (hg19)	Stop (hg19)	<i>P</i>	Bonf.	<i>P</i>	Bonf.	<i>P</i>	Bonf.	<i>P</i>	<i>Z</i>
rs9349379	5.2×10 ⁻¹⁵	<i>PHACTR1</i>	6	12717893	13288645	1.7×10 ⁻⁴	1.00	5.6×10 ⁻⁵	1.00	1.5×10 ⁻⁴	1.00	1.1×10⁻¹¹	6.8
rs11172113	2.0×10 ⁻¹⁰	<i>LRP1</i>	12	57522276	57607134	2.5×10 ⁻³	1.00	2.5×10 ⁻³	1.00	4.1×10 ⁻³	1.00	2.7×10⁻¹⁰	6.3
		<i>STAT6</i>	12	57489260	57525922	3.7×10 ⁻⁶	0.07	2.4×10⁻⁶	0.04	2.0×10 ⁻⁵	0.38	8.3×10 ⁻²	-1.7
rs17249754	5.9×10 ⁻⁹	<i>ATP2B1</i>	12	89981828	90102608	3.8×10 ⁻³	0.70	7.4×10 ⁻⁵	1.00	7.9×10 ⁻⁵	1.00	3.7×10⁻⁶	-4.6
rs6580732	2.2×10 ⁻⁹	<i>LIMA1</i>	12	50569571	50677329	2.4×10⁻⁶	0.04	5.7×10⁻⁷	0.01	3.0×10⁻⁷	0.01	7.0×10 ⁻³	2.7
		<i>ATF1</i>	12	51157493	51214905	7.7×10 ⁻⁶	0.14	7.3×10⁻⁷	0.01	1.5×10⁻⁶	0.03	2.0×10 ⁻³	-3.1
		<i>GPD1</i>	12	50497602	50505102	2.8×10 ⁻⁶	0.05	7.3×10⁻⁷	0.01	8.2×10⁻⁷	0.02	N/A	N/A
rs2424245	4.0×10 ⁻⁷	<i>SLC24A3</i>	20	19193290	19703581	4.5×10 ⁻⁶	0.08	4.7×10 ⁻⁴	1.00	4.8×10 ⁻⁵	0.89	5.1×10⁻⁹	-5.8

977
978
979
980
981
982

Table 3. Candidate causal variants at FMD associated loci

All variants with at least suggestive association ($P < 5 \times 10^{-6}$) in the global FMD association studies and in high LD ($r^2 \geq 0.5$) with the lead SNP of each locus were tested for overlap with open chromatin regions in coronary artery tissue, carotid/coronary artery derived primary cells, dermal fibroblasts and histone marks in artery tissues (aorta, coronary or tibial arteries) from ENCODE databases. N SNPs indicate the number of SNPs tested at each locus. Best P indicates the lowest P -value of the SNP in the three GWAS (all FMD cases, multifocal FMD or women FMD). Grey colour indicates overlap of the variant with at least one dataset of the corresponding category. *: Variant with genome-wide significant association with FMD.

Locus	SNP information						ATAC-Seq						Histone ChIP-Seq			
	Lead SNP	N SNPs	SNP	Chr	Pos (hg38)	LD (r^2)	Best P	Coronary Artery		Carotid Artery		Dermal Fibroblasts	Any arteries			
								Whole Tissue	SMC	EC	SMC	EC	HDF	H3K4me1	H3K4me3	H3K27ac
rs9349379	1	rs9349379*	6	1290372	1.00	5.2×10^{-15}										
rs11172113	3	rs4759275	12	5713197	0.76	2.9×10^{-6}										
		rs11172113*	12	5713350	1.00	2.0×10^{-10}										
rs17249754	30	rs11105352*	12	8963268	1.00	8.0×10^{-9}										
		rs11105353*	12	8963268	1.00	8.0×10^{-9}										
		rs11105354*	12	8963274	1.00	6.8×10^{-9}										
		rs73437382	12	8970916	0.50	1.4×10^{-6}										
		rs2280715	12	8970992	0.51	1.8×10^{-6}										
rs6580732	117	rs7967705	12	5011762	0.72	2.6×10^{-7}										
		rs7297421	12	5012514	0.72	4.0×10^{-7}										
		rs7308356	12	5014582	0.73	4.3×10^{-7}										
		rs12815871	12	5015716	0.72	1.7×10^{-7}										
		rs7301566*	12	5018786	0.95	1.3×10^{-9}										
		rs2358538	12	5019284	0.83	8.9×10^{-8}										
		rs4459386*	12	5020116	1.00	2.9×10^{-9}										
		rs1862042	12	5021144	0.87	4.2×10^{-7}										
		rs10783342*	12	5023468	1.00	6.8×10^{-9}										
		rs7309519	12	5025849	0.87	9.7×10^{-8}										
		rs10747586	12	5058978	0.67	8.2×10^{-7}										
		rs7305655	12	5061150	0.67	8.7×10^{-7}										
		rs2700479	12	5062668	0.67	4.2×10^{-7}										
		rs2684889	12	5068609	0.67	3.1×10^{-7}										
		rs1109726	12	5076476	0.56	1.1×10^{-6}										

Figure 1




Figure 2





Figure 3



medRxiv preprint doi: <https://doi.org/10.1101/2020.09.16.20195701>; this version posted September 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Figure 4












Figure 5

a



b




Figure 6

